ENCODE logo courtesy of the National Human Genome Research Institute
The Human Genome Project has been one of the great scientific pursuits of the 21rst century. One aspect of this Project is to understand the role of functional and dysfunctional (pathologic) “elements” in the genome as to predispositions and causation of disease. Concepts are changing and discoveries are being made with increasing frequency.
Preventive and interventional clinical trials and therapies will be one of the ultimate “deliverables” of the Human Genome Project. To facilitate global implementation of new discoveries and concepts of the Human Genome Project to real patients, HUMENCODE ® is medical services provided by licensed physicians who practice preventive, diagnostic and therapeutic healthcare based upon “evidence” of benefit from the Human Genome Project. Medical services include routine laboratory testing of blood, body fluid and tissue samples as well as sophisticated tumor markers such as: (1) ALK gene rearrangements for Non-small cell lung cancer and anaplastic large cell lymphoma, (2) Alpha-fetoprotein (AFP) for liver cancer and germ cell tumors, (3) BCR-ABL fusion gene for Chronic Myelogenous Leukemia, (4) CA-125 for ovarian cancer, (5) Carcinoembryonic antigen (CEA) for colorectal and breast cancer, (6) Estrogen receptor (ER)/progesterone receptor (PR) for breast cancer, (7) HER2/neu for breast, esophageal and gastric cancer, (8) KRAS mutation analysis for colorectal cancer and non-small cell lung cancer, and (9) KIT for gastro-intestinal and mucosal melanoma. New tests will be added when validated to be clinically useful in patient care and genetic counseling of family members.
If you or your patients would like additional information about HUMENCODE ®, our company, our diversified professional and technical pathology and clinical laboratory testing services, please feel free to contact Byron L. Barksdale, M.D. at 308-530-3759 or : email@example.com
Copyright, 2012-2016 Internet Physician, Inc. All rights reserved worldwide.